HDAC9 and Parkinson disease: Additionally, given the implication of the use of HDAC (such as SIRT 2) inhibitors for neuroprotection in PD, we quantify HDAC expression in the SNpc of these same cases, to determine if the expression level of these enzymes changes with PD development.